Übersichtsarbeit · Review Article
Resektionsausmaß und Therapiekonzept bei Verdacht auf hereditäres, nichtpolypöses kolorektales Karzinom – Sicht des GastroenterologenAndus T.
Klinik für Allgemeine Innere Medizin, Gastroenterologie, Hepatologie und internistische Onkologie, Krankenhaus Bad-Cannstatt, Klinikum Stuttgart, Deutschland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
In patients with hereditary non-polypous colorectal carcinoma (HNPCC) the lifetime risk for colorectal cancer amounts to approximately 60-80%. HNPCC patients very rarely develop colorectal cancer before the age of 25 years. Therefore, surveillance should start in this age. In a controlled study continuous surveillance colonoscopies every 3 years significantly reduced the colorectal cancer risk and mortality and proved to be an effective and safe method of cancer prevention in HNPCC patients. Preventive colectomy or proctocolectomy, theoretically would be an alternative option, similarly as in the case the of familial adenomatous polyposis (FAP). However, in contrast to FAP where the risk for intestine cancer is 100% approximately 20-40% of the HNPCC patients would be operated who will never develop colorectal cancer. Therefore, according to German guidelines preventive colectomy and/or proctocolectomy cannot be recommended since nearly all colorectal cancers are discovered by regular surveillance colonoscopies in the stage UICC I/II or even as premalignant adenomas, showing only incomplete penetrance. If colorectal cancer is diagnosed, patients are operated on the basis of surgical criteria. However, the risk of colorectal cancer in the remaining large intestine and the risk of extracolonic neoplasias remain clearly increased. Therefore, an intensive postoperative surveillance program must be supplied to these patients.
Type of Resection and Concept of Treatment in Index Patients with Hereditary Non-Polypous Colorectal Carcinoma – Gastroenterologist’s View
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.